Second allogeneic hematopoietic SCT for relapsed ALL in children

Area of Science:

• Pediatric Hematology-Oncology
• Stem Cell Transplantation
• Leukemia Research

Background:

• Second allogeneic stem cell transplant (allo-SCT) is a potential cure for relapsed acute lymphoblastic leukemia (ALL).
• The efficacy and role of a second allo-SCT in pediatric ALL remain incompletely defined.

Purpose of the Study:

• To evaluate the outcomes of a second allo-SCT in pediatric patients with relapsed ALL.
• To identify factors influencing survival after a second allo-SCT for pediatric ALL.

Main Methods:

• Retrospective analysis of 171 pediatric patients undergoing a second allo-SCT for relapsed ALL.
• Evaluation of overall survival (OS), cumulative incidence of relapse, and non-relapse mortality.
• Analysis of prognostic factors including age, relapse timing, remission status, conditioning intensity, GVHD, and donor type.

Main Results:

• Two-year OS was 29.4%, with a 44.1% cumulative incidence of relapse and 18.8% non-relapse mortality.
• Relapse occurred significantly faster after the second SCT compared to the first (117 vs. 164 days).
• Favorable prognostic factors for longer survival included younger age (≤9 years), late relapse (>180 days), complete remission (CR) at second SCT, and myeloablative conditioning.

Conclusions:

• A second allo-SCT is a viable treatment option for pediatric ALL patients in CR, particularly those experiencing late relapse.
• Younger age and late relapse are key predictors of better outcomes following a second SCT for relapsed pediatric ALL.
• Further research may optimize patient selection and conditioning regimens to improve second SCT success rates.